OP0226 Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept in Patients with Active Rheumatoid Arthritis (RA) despite Methotrexate (MTX) Therapy
James R. O’Dell(University of Nebraska Medical Center), Barbara Finck(Coherus BioSciences (United States)), Ingrid Louw(Cape Town Science Centre), Tsutomu Takeuchi(Keio University), Т Д Тябут(9th City Clinical Hospital), M Oribe, Yoshiya Tanaka(University of Occupational and Environmental Health Japan), M. Kai(Yazaki (United States)), S. Nakashima(Daiichi-Sankyo (Japan))
Cited by 14
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k